AIG Promotes Peter Hancock to CEO

American International Group Inc. (AIG) promoted Peter Hancock to chief executive officer as the company focuses on growth after his predecessor stabilized the insurer and paid back a 2008 government bailout.

Hancock, 55, oversees property-casualty insurance and will be CEO and president as of Sept. 1, the New York-based firm said yesterday. He previously spent 20 years at a predecessor to JPMorgan Chase & Co., where he established the derivatives group. He replaces Robert Benmosche, 70, who stayed on longer than previously planned.

“AIG is no longer burning down, and the challenge for AIG and for Peter as CEO is to continue to drive the transformation,” Josh Stirling, an analyst at Sanford C. Bernstein & Co., said in a phone interview. “People are very much looking for real signs of progress.”

Hancock takes over a company that has shrunk by half since 2008 as Benmosche sold assets and cut jobs to simplify the business and repay a rescue that swelled to $182.3 billion. The firm is now focused on global property-casualty coverage and U.S. life insurance and retirement products. Jay Wintrob heads the life unit and intends to stay with AIG, though he is disappointed he wasn’t selected as the company’s CEO, Chairman Steve Miller told reporters.

AIG slipped 0.9% to $54.53 at 10:24 a.m. in New York. That compares with about $11.39 on Aug. 3, 2009, the day AIG announced Benmosche’s hiring.

Finance, Risk

Hancock joined AIG in 2010 to oversee finance and risk. In 2011, he was promoted to run the property-casualty business, an operation that became increasingly important to AIG as the company sold non-U.S. life insurers and a plane-leasing unit.

“Property and casualty is not only our largest business, but it’s our most complex business and it’s the one that can most effect the future success of AIG,” Miller said. “He’s the one who has dealt with the thorniest issues.”

Hancock sought to expand in less capital-intensive lines of insurance after AIG was burned by higher-than-expected costs in commercial segments including workers’ compensation, where claims emerge years after policies are sold. He targeted emerging markets and sales to consumers.

Hancock said in an interview that he plans to focus on customer segments and products where AIG is “properly rewarded” for taking risks. “And to do that we are investing in research and development to really understand emerging risks better.”

‘Too Long’

The insurer said in 2010 that Benmosche was undergoing chemotherapy for cancer, increasing the urgency for succession planning. Benmosche, who previously postponed plans for retirement, said his latest intent was to stay on until February, and that succession was accelerated because “the transition was taking too long.” The board’s vote was June 9, he said in an interview.

He said that “things are going OK” with treatment for his cancer and that Hancock’s hiring represents continuity. “If the board wanted a dramatic change, they would have looked for someone outside,” he said.

Hancock becomes the company’s sixth CEO since 2005, when Maurice “Hank” Greenberg stepped down amid accounting probes after building AIG into the world’s largest insurer. Martin Sullivan left in 2008 after underestimating the potential for losses on bets tied to subprime mortgages. Robert Willumstad lasted only months, and Edward Liddy, who took over with the bailout, was replaced by Benmosche the next year.

Benmosche previously led MetLife Inc., the largest U.S. life insurer. He came out of retirement in August 2009 to take over AIG, which was reeling from losses, and set the company on the road to repaying taxpayers. Along the way, Benmosche became the most outspoken AIG chief since Greenberg.

‘So Much Trouble’

Benmosche sparred with government overseers, rebelled against U.S.-imposed pay caps that he said limited the firm’s ability to retain staff, threatened to quit and succeeded in ousting then-Chairman Harvey Golub with a him-or-me showdown.

“I create so much trouble, don’t I?” Benmosche told employees at a 2009 meeting. “That’s my job.”

He also criticized lawmakers for contributing to the public backlash against bonuses the firm paid, calling them “crazies down in Washington.”

The CEO’s intent was to show employees somebody would stick up for them, said Ernest Patrikis, AIG’s general counsel from 1999 through 2006 and now partner at White & Case LLP.

“What Benmosche did was get employee’s morale on track,” Patrikis said. “You needed someone to punch back.”

He also reinstated the dividend and reduced debt. Benmosche sold units including American Life Insurance Co. in 2010 and International Lease Finance Corp. last month.

No Anvil

“I don’t think it was a coincidence that this announcement was made at the first board meeting held post-ILFC close,” Charles Sebaski, an analyst at BMO Capital Markets, said in an interview. “This was the last leg of non-core assets that had to be dealt with, and now he can hand over a clean entity. He doesn’t walk out the door with an anvil over the new CEO’s head.”

The insurer’s market value is about $80 billion, compared with $148 billion at the end of 2007. The employee count is down 45% in the six years ended Dec. 31 to 64,000.

Hancock has sought to build relations with regulators, including the Federal Reserve, which helped bail out the company. The central bank will oversee AIG because it was deemed a systemically important institution, and Hancock said in 2011 that his company was working to become “Fed ready.”

Hot Paper Companies To Buy For 2015

He reiterated last month his embrace of the supervision, in contrast with MetLife CEO Steven Kandarian who has spoken out against what he sees as the risk of over-regulation.

‘High Standards’

The Fed does “a good job of helping us coordinate our message to the other regulators, also, importantly, to rating agencies,” Hancock said at an investor conference in May. “We’re being held to very high standards there and we welcome that.”

Hancock was raised in Hong Kong and attended Oxford University, where he earned his bachelor of arts degree in politics, philosophy and economics, AIG said in the statement.

Jon Diat, a spokesman for the company, said it is too early to comment on who would be the next leader of the property-casualty operation. Benmosche is expected to resign from the board and take an advisory role with the company, AIG said.

“Benmosche stepped into the crucible when he took over at AIG,” said David Havens, a managing director and credit analyst at Los Angeles-based investment bank Imperial Capital LLC. “Hardly anyone expected AIG to succeed to the extent it has, and a great deal of the credit should go directly to him.”

---

Check out AIG Advisor Group CEO: ‘Comfortable With Parent Company’ on ThinkAdvisor.

Top 5 Paper Companies To Own For 2014

Small cap stocks New China Global (OTCMKTS: NCGI), RealBiz Media Group Inc (OTCMKTS: RBIZ) and SofTech, Inc (OTCMKTS: SOFT) sank 21.11%, 14.81% and 10.89%, respectively, last Friday. Moreover, two of these three small caps have been the subject of paid promotions or investor relations activities, but this week is the start of a new trading week and anything can happen. So will these three small cap stocks keep sinking? Here is a closer look to help you decide on an investing or trading strategy:

New China Global (OTCMKTS: NCGI) Is Promoting and Expanding Its Services

Small cap New China Global offers a wide variety of services from academic research papers and dissertations to professional development or translation services. On Friday, New China Global sank 21.11% to $0.0355 for a market cap of $3,500 plus NCGI is up 1,083.3% over the past year and up 610% in intermittent trading over the past five years according to Google Finance.

Top Defensive Stocks To Watch Right Now: Cornerstone Progressive Return Fund(CFP)

Cornerstone Progressive Return Fund is a closed-ended equity fund of fund launched and managed by Cornerstone Advisors, Inc. The fund invests funds investing in the public equity markets of the United States. It invests in stocks of companies operating across diversified sectors. Cornerstone Progressive Return Fund was formed on April 26, 2007 and is domiciled in the United States.

Advisors' Opinion:

• [By Dan Caplinger]

  But you can see in several places the consequences of the stampede toward high yield. Here are just a few:

  Closed-end funds Cornerstone Progressive (NYSEMKT: CFP  ) and Pimco High Income (NYSE: PHK  ) both make fixed payments back to fund shareholders on a monthly basis, and their distribution yields are truly extraordinary, at about 17% and 12%, respectively. Those dividends have enticed shareholders to pay $1.30 to $1.40 or more for each $1 of assets in the funds. Yet during most months, a substantial portion of those distribution payments has simply been a return of investor capital rather than true income from the funds' investments. A recent study discussed in The Wall Street Journal found that returns on a portfolio with a combined value and dividend-income strategy outperformed a strategy focused more exclusively on maximizing dividends by an average of 1.7 percentage points per year, a huge edge in long-run returns. In the dividend ETF arena, most funds tend to focus on maximizing yield. Although the popular Vanguard Dividend Appreciation (NYSEMKT: VIG  ) ETF bucks the trend by screening first for consistent dividend growth and only then looking at yield as a factor, many rival ETFs start with high-yielding stocks as their baseline and only then consider other desirable traits. Others focus solely on high-dividend niches of the market, such as iShares FTSE NAREIT Mortgage-Plus (NYSEMKT: REM  ) and its concentration on high-yield mortgage REITs.

  When dividend stocks get too popular, their prices get out of line with both their dividend income and the fundamentals of the businesses that underlie those stocks. In simpler terms, when dividend stocks become bad values, it's time to consider looking elsewhere for a margin of safety.

Top 5 Paper Companies To Own For 2014: Fibria Celulose SA (FBR)

Fibria Celulose S.A. (Fibria), formerly Votorantim Celulose e Papel S.A., incorporated on July 25, 1941, is a producer of market pulp. During the year ended December 31, 2010, Fibria produced 5,054 kilotons of eucalyptus pulp (including 50.0% of the pulp production of Veracel). The Company also produces coated and uncoated paper, carbonless paper and thermal paper at its Piracicaba paper mill, located in the State of Sao Paulo with an annual production capacity of 190 kilotons. During 2010, it produced 115 kilotons of paper products and recorded consolidated net revenues. Fibria produces bleached eucalyptus kraft pulp at three pulp mills, the Aracruz pulp mill located in the State of Espirito Santo, which has an annual production capacity of 2.3 million tons; the Tres Lagoas pulp mill located in the State of Mato Grosso do Sul, which has an annual production capacity of 1.3 million tons, and the Jacarei pulp mill located in the State of Sao Paulo, which has an annual production capacity of 1.1 million tons. The Company has a 50% interest in Veracel, which owns and operates a pulp mill in the municipality of Eunapolis, State of Bahia, with an annual production capacity of 1.1 million tons.

Pulp

Fibria produces bleached eucalyptus kraft pulp from planted eucalyptus trees. Bleached eucalyptus kraft pulp is a range of hardwood pulp. Eucalyptus is a hardwood tree, and its pulp has short fibers and is generally suited to manufacturing tissue, coated and uncoated printing and writing paper and coated packaging boards. Short fibers are optimal for manufacturing wood-free paper with good printability, smoothness, brightness and uniformity. Market pulp is the pulp sold to producers of paper products. Kraft pulp is pulp produced in a chemical process using sulphate. During 2010, it produced 5,054 kilotons of pulp (including 50.0% of the pulp production of Veracel).

Paper

During 2010, Fibria produced 115 kilotons of paper. The Company produced coated printing an! d writing paper, which is a coated woodfree paper used for promotional materials, folders, internal sheets and cover of magazines, books, tabloids, inserts and mailing; uncoated printing and writing paper, which is a uncoated woodfree paper in reels and sheets; carbonless paper, which is used to produce multi-copy forms, POS, invoices and other applications in place of traditional carbon paper, and thermal paper, which is traditionally used in fax machines; POS, bar code labels, toll tickets, water and gas bills and receipts for automated teller machines (ATMs) and credit card machines. It manufactures thermal paper products with technology licensed byOji Paper Co., Ltd (Oji Paper).

The Company competes with APRIL, Arauco, APP, Georgia Pacific, CMPC, Sodra, Stora Enso, Weyerhaeuser and Suzano.

Advisors' Opinion:

• [By Seth Jayson]

  Fibria Celulose (NYSE: FBR  ) reported earnings on July 24. Here are the numbers you need to know.

  The 10-second takeaway
  For the quarter ended June 30 (Q2), Fibria Celulose met expectations on revenues and missed expectations on earnings per share.

Top 5 Paper Companies To Own For 2014: Fibria Celulose SA (FIBR3)

Fibria Celulose SA, formerly Votorantim Celulose e Papel SA, is a Brazil-based company involved in the production and sale of short fiber pulp. The Company operates pulp manufacturing plants in Aracruz (Espirito Santo), Tres Lagoas (Mato Grosso do Sul), Jacarei (Sao Paulo) and Veracel (Bahia). Additionally, the Company is engaged in the cultivation of eucalyptus. It has plantations in the Brazilian states of Sao Paulo, Minas Gerais, Rio de Janeiro, Mato Grosso do Sul, Bahia and Espirito Santo. In 2011, the Company sold a business unit active in paper production. The Company has a number of subsidiaries in Brazil and abroad, including Normus Empreendimentos e Participacoes Ltda, Fibria Overseas Finance Ltd and Fibria Celulose (USA) Inc, among others. On October, 2013, the Company announced merger by incorporation of Normus Empreendimentos e Participacoes Ltda, a wholly-owned subsidiary of the Company, in order to simplify the corporate structure. Advisors' Opinion:

• [By Julia Leite]

  Fibria Celulose SA (FIBR3), the world�� largest pulp producer, climbed after settling a tax dispute with Brazil over profits at its foreign units. Iron-ore producer Vale SA (VALE5) gained before a report due this weekend forecast to show manufacturing is still expanding in China, the company�� main export market.

• [By Harry Suhartono]

  The Ibovespa dropped 1.8 percent as iron-ore producer Vale SA (VALE5), whose main export market is China, snapped a two-day gain. Pulp producer Fibria Celulose SA (FIBR3) retreated after posting quarterly earnings that trailed analysts��estimates. Brazil plans to sell dollar bonds due in 2025, creating a new benchmark security in international markets, and buy back notes maturing in as little as four years.

Top 5 Paper Companies To Own For 2014: Domtar Corp (UFS)

Domtar Corporation, incorporated on August 16, 2006, designs, manufactures, markets and distributes a range of fiber-based products, including communication papers, specialty and packaging papers and adult incontinence products. The Company operates in three business segments: Pulp and Paper, Distribution and Personal Care. Its Pulp and Paper segment consists of the manufacturing, sale and distribution of communication, specialty and packaging papers, as well as softwood, fluff and hardwood market pulp. The Company�� Distribution segment includes the purchasing, warehousing, sale and distribution of its paper products and those of other manufacturers. These products include business and printing papers, certain industrial products and printing supplies. Its Personal Care segment consists of the manufacturing, sale and distribution of adult incontinence products.The Company is an integrated marketer and manufacturer of uncoated freesheet paper in North America for a variety of customers, including merchants, retail outlets, stationers, printers, publishers, converters and end-users. The Company produces incontinence care products marketed primarily under the Attends brand. The Company owns and operates Ariva. On May 10, 2012, the Company acquired EAM Corporation. In June 2013, the Company announced the completion of its acquisition of Xerox Corp paper and print media products business in the United States and Canada. In July 2013, Domtar Corp announced that completion of the acquisition of Associated Hygienic Products (AHP) from DSG International. In January 2014, the Company acquired Laboratorios Indas, SAU.

Pulp and Paper

The Company produces 4.2 million metric tons of hardwood, softwood and fluff pulp at 12 of its 13 mills. The majority of its pulp is consumed internally to manufacture paper and consumer products, with the balance being sold as market pulp. The Company also purchases papergrade pulp from third parties. The Company has 10 pulp and paper mills (eight in the! United States and two in Canada), with an annual paper production capacity of approximately 3.4 million tons of uncoated freesheet paper. Its paper manufacturing operations are supported by 15 converting and distribution operations, including a network of 12 plants located offsite of its paper making operations. In addition, it has forms manufacturing operations at three offsite converting and distribution operations. Approximately 81% of its paper production capacity is in the United States, and the remaining 19% is located in Canada.

The Company produces market pulp in excess of its internal requirements at its three non-integrated pulp mills in Kamloops, Dryden, and Plymouth, as well as at its pulp and paper mills in Espanola, Ashdown, Hawesville, Windsor, Marlboro and Nekoosa. The Company sells approximately 1.6 million metric tons of pulp per year depending on market conditions. Approximately 50% of its trade pulp production capacity is in the United States, and the remaining 50% is located in Canada. The fiber used by its pulp and paper mills in the United States is hardwood and softwood, both being readily available in the market from multiple third-party sources. The fiber used at its Windsor pulp and paper mill is hardwood originating from a variety of sources, including purchases on the open market in Canada and the United States, contracts with Quebec wood producers��marketing boards, public land where it has wood supply allocations and from its private lands. The softwood and hardwood fiber for its Espanola pulp and paper mill and the softwood fiber for its Dryden pulp mill, is obtained from third parties, directly or indirectly from public lands, through designated wood supply allocations for the pulp mills. The fiber used at the Company�� Kamloops pulp mill is all softwood, originating from third-party sawmilling operations in the southern-interior part of British Columbia.

The Company uses various chemical compounds in its pulp and paper manufacturing facili! ties that! it purchases, primarily on a central basis, through contracts. For pulp manufacturing, it uses numerous chemicals, including caustic soda, sodium chlorate, sulfuric acid, lime and peroxide. For paper manufacturing, it also uses several chemical products, including starch, precipitated calcium carbonate, optical brighteners, dyes and aluminum sulfate. It owns power generating assets, including steam turbines, at all of its integrated pulp and paper mills, as well as hydro assets at four locations: Espanola, Ottawa-Hull, Nekoosa and Rothschild. The Company�� business papers include copy and electronic imaging papers, which are used with ink jet and laser printers, photocopiers and plain-paper fax machines, as well as computer papers, preprinted forms and digital papers. These products are primarily for office and home use. The Company�� commercial printing and publishing papers include uncoated freesheet papers, such as offset papers and opaques. These uncoated freesheet grades are used in sheet and roll fed offset presses across the spectrum of commercial printing end-uses, including digital printing. Its publishing papers include tradebook and lightweight uncoated papers used primarily in book publishing applications, such as textbooks, dictionaries, catalogs, magazines, hard cover novels and financial documents. Design papers, a sub-group of commercial printing and publishing papers, have features of color, brightness and texture and are targeted towards graphic artists, design and advertising agencies, primarily for special brochures and annual reports. These products also include base papers that are converted into finished products, such as envelopes, tablets, business forms and data processing/computer forms.

The Company also produces paper for several specialty and packaging markets. These products consist primarily of base stock for thermal printing, flexible packaging, food packaging, medical gowns and drapes, sandpapers backing, carbonless printing, labels and other coating a! nd lamina! ting applications. The Company also manufactures papers for industrial and specialty applications, including carrier papers, treated papers, security papers and specialized printing and converting applications. The Company sells business papers primarily to paper stationers, merchants, office equipment manufacturers and retail outlets. The Company distributes uncoated commercial printing and publishing papers to end-users and commercial printers, mainly through paper merchants, as well as selling directly to converters. The Company sells its specialty and packaging papers mainly to converters, who apply a further production process, such as coating, laminating, folding or waxing to its papers before selling them to a variety of specialized end-users.

Distribution

The Company's Distribution business involves the purchasing, warehousing, sale and distribution of the Company's various products and those of other manufacturers. These products include business, printing and publishing papers and certain packaging products. These products are sold to diverse customer base, which includes small, medium and large commercial printers, publishers, quick copy firms, catalog and retail companies and institutional entities. The Company's Distribution business operates in the United States and Canada under a single banner and umbrella name, Ariva. Ariva operates throughout the Northeast, Mid-Atlantic and Midwest areas from 16 locations in the United States, including 12 distribution centers serving customers across North America.

Personal Care

The Company's Personal Care business sells and manufactures adult incontinence products and distributes disposable washcloths marketed primarily under the Attends brand name. The Company is a supplier of adult incontinence products sold into North America and Northern Europe, selling to hospitals (acute cares) and nursing homes (long-term care) and the Company has a growing presence in the homecare and retail channels. The C! ompany op! erates two manufacturing facilities, with each having the ability to produce multiple product categories. The Company also has a research and development facility and production lines which manufacture high quality airlaid and ultrathin laminated absorbent cores.

Advisors' Opinion:

• [By Rich Duprey]

  Specialty paper maker�Domtar� (NYSE: UFS  ) �wrote it all down yesterday: it�will pay a�regular quarterly dividend�of $0.55 per share that's 22% higher than the $0.45 per share payout it made last quarter. Shareholders of record on June 14 will receive the new dividend rate at the close of business on July 15.

How to Kill a Zombie (Foreclosure) in Your Neighborhood

Getty Images Millions of us love zombies in the movies or on "The Walking Dead," but when they start showing up in your neighborhood, that's where the fun ends. And if you think rotting corpses are scary when they start moving around, they're almost as bad when they're houses people moved away from. Of course, I am referring to zombie foreclosures: properties where a foreclosure was initiated and the homeowner has walked away, but the bank hasn't completed the process, leaving it in limbo for months or even years. In general, the former occupants don't even realize that, technically, they still own the house. The problem with these undead domiciles is that, once abandoned, they quickly fall into disrepair and become targets for vandalism, graffiti and squatters, all of which can bring down the value of surrounding homes. According to Realty Trac, one out of every five homes currently in foreclosure is a zombie property, and in certain metro areas in states like Florida and Nevada -- hit especially hard when the housing bubble burst in 2008 -- that number can be as high as one out of three. If you have a suspect property in your neighborhood, there are a few things you can do to confirm it's a zombie foreclosure. First, search for a foreclosure file at your local courthouse or recorder's office. You'll want to pay attention to the date of the last recorded action on that file, and what type of action it was. If you see either an "Order of Sale" or a "Postponement of Sale" as the last action and it is more than 90 days old, you might be dealing with a zombie foreclosure. Next, contact the utility companies and ask about the account status of the property in question. Though it's not a definitive indicator, homes with no water or power are very likely to be vacant. Finally, do a visual inspection of the property, ideally with some like-minded neighbors. Obviously, an overgrown yard, accumulated debris, broken or boarded up windows, padlocked doors, signs or notices from servers, will serve to indicate the property is abandoned. If after all this, you're still not sure if you are dealing with a zombie, conduct a title search to determine the ownership status –- something many neighborhood real estate agents will be happy to do for you. Aim for the Brain Once you've determined that you are in fact dealing with a zombie foreclosure her are some potential ways you can kill it. Notify local contractors, developers, or community redevelopment firms about the property. Zombies can be ideal investment candidates for folks who specialize in rehabbing and flipping homes. Also, check your state and local laws regarding foreclosures –- something, once again, that a friendly local real estate agent can help you with. Some areas have laws on the books that require a foreclosure to be completed by the note holder within 90 days of the original sale date. If this is the case in your area, and the property is past that 90 day mark, contact the servicer of the loan. Most major servicers have a property preservation department, so notify them that their zombie is on the loose. The civil codes vary, but in general, if the note holder fails to follow through on a pending foreclosure, it can be fined. That's usually enough to light a fire under a bank, but if it still doesn't take action, you can then file a complaint against it with the Consumer Financial Protection Bureau. If none of these actions gets the problem solved, your final option is to petition the Clerk of the Court to order the completion of the foreclosure. This course requires legal representation, so you will have to either contact your local city official or an attorney to more the process forward. In all cases however, the more people you have on your side the better your chances are. Agencies, officials, and even banks are more likely to respond to your requests if they know you have a large number of voters and consumers standing behind you. So get your fellow homeowners together and get organized. As the band of survivors on "The Walking Dead" knows all too well, it takes a team to effectively fight off zombies.

Nokia Results Slashed by Discontinued Operations

Nokia Corp. (NYSE: NOK) reported fourth-quarter and interim full-year fiscal 2013 results from continuing operations before markets opened Thursday. Results exclude the company’s Devices & Services (handset) division, which the firm has agreed to sell to Microsoft Corp. (NASDAQ: MSFT) for around $7.2 billion. Including the discontinued operations, however, does not help Nokia’s story much though.

For the quarter, the mobile handset maker posted adjusted diluted earnings per share (EPS) of €0.08 (about $0.11) on revenues of €3.5 billion (about $4.77 billion). In the same period a year ago, the company reported EPS of $0.08 on revenues of $10.57 billion). Fourth-quarter results compare to the Thomson Reuters consensus estimates for EPS of $0.04 and $8.62 billion in revenues. The consensus estimates do not include the handset business as a discontinued operation.

For the full year, Nokia posted EPS of €0.21 (about $0.29) on revenues of €12.7 billion (about $17.32 billion). The consensus estimate called for EPS of $0.07 on revenues of $31.16 billion.

Fourth-quarter sales in the Devices & Services division totaled €2.6 billion (about $3.55 billion) and full-year sales from discontinued operations totaled €10.7 billion (about $14.59 billion). Added to sales from continuing operations, revenues totaled $8.32 billion for the quarter and $31.91 billion for the year. Revenues fell 29% in Nokia’s handset business.

Nokia’s largest remaining business, Nokia Solutions and Networks (NSN), posted fourth-quarter revenues of €3.1 billion ($4.21 billion), down 22% from the same period a year ago and up 20% sequentially. This is what caused investors to shy away from the stock in premarket trading Thursday.

The company’s chairman/interim CEO said:

During the fourth quarter, Nokia’s continuing businesses produced a healthy underlying operating margin of 12%. While the first quarter of the year is seasonally weak for our continuing operations, we continue to expect the closing of the Microsoft transaction to significantly improve Nokia’s earnings profile.

The strength of NSN’s underlying profitability highlights just how fundamentally different the company is today, compared with two years ago when it started its restructuring and transformation program. Today, we are more focused, more innovative and more disciplined. With these fundamental elements in place, we believe NSN is well-positioned to deliver solid business performance for the year ahead.

The new Nokia will be a much smaller company, with sales in the range of $17 billion to $20 billion, compared with past sales of more than $30 billion. Profitability appears to be reasonable, but the warning about a seasonally weak first quarter will not encourage many investors to bid the stock up.

Top Small Cap Stocks To Own Right Now

Nokia shares were down about 3.25% in premarket trading, at $7.45 in a 52-week range of $3.02 to $8.20. Thomson Reuters had a consensus analyst price target of around $7.90 before this report. Nokia’s shares have nearly doubled since the handset division’s sale to Microsoft was announced last summer.

Top Mid Cap Stocks To Watch Right Now

About�a week ago, Wall Street was biting small cap pet stock Petmed Express Inc (NASDAQ: PETS) for not living up to its earnings expectations�- meaning it might be worth taking a closer look at the stock�and compare its performance with other pet stocks like mid cap PetSmart, Inc (NASDAQ: PETM) and small cap VCA Antech Inc (NASDAQ: WOOF). I should also mention that we have recently added Petmed Express to our SmallCap Network Elite Opportunity (SCN EO) portfolio because we think the stock is undervalued in the pet space and has tremendous growth potential�moving forward.

What is Petmed Express Inc?

Small cap Petmed Express was founded in 1996 and is America�� largest pet pharmacy, delivering prescription and non-prescription pet medications and other health products for dogs and cats at competitive prices direct to the consumer through its 1-800-PetMeds toll free number and on the Internet through its website at www.1800petmeds.com. The company is a�licensed pharmacy to dispense prescription medications in all 50 states with over 3,000 SKUs, including a variety of private label products all made in the United States.

Top 5 Consumer Service Stocks To Invest In Right Now: Kansas City Southern (KSU)

Kansas City Southern, through its subsidiaries, engages primarily in the freight rail transportation business. It operates north/south rail between Kansas City, Missouri, and various ports along the Gulf of Mexico in Alabama, Louisiana, Mississippi, and Texas in the midwest and southeast regions of the United States. The company also operates direct rail passageway between Mexico City and Laredo in Texas, serving various Mexico?s industrial cities and 3 of its shipping ports; and a 157-mile rail line extending from Laredo, Texas to the port city of Corpus Christi, Texas, as well as owns the northern half of the rail bridge at Laredo, Texas. In addition, Kansas City Southern holds a concession to operate a 47-mile railroad located adjacent to the Panama Canal, as well as operates and promotes commuter and tourist passenger services. Further, the company operates a bulk materials handling facility with deep-water access to the Gulf of Mexico at Port Arthur, Texas that stores and transfers petroleum coke from rail cars to ships primarily for export; and a railroad wood tie treatment facility. It serves customers conducting business in various industries, including electric-generating utilities, chemical and petroleum products, industrial and consumer products, agriculture and mineral products, automotive products, and intermodal freight transportation. The company was formerly known as Kansas City Southern Industries, Inc. and changed its name to Kansas City Southern in 2002. Kansas City Southern was founded in 1962 and is based in Kansas City, Missouri.

Advisors' Opinion:

• [By Doug Ehrman]

  Kansas Southern (NYSE: KSU  ) is reporting on Friday. The street expects Kansas Southern to report EPS of $0.88, a 17% bump on a revenue increase of 4.4% to $571.3 million. One of the primary catalysts for the increase is the shale oil boom that is most likely to shake up the industry. Where Union Pacific is benefiting from increased coal shipments, largely on the West Coast, Kansas Southern transports oil.

• [By Sara Murphy]

  CSX (NYSE: CSX  ) and Kansas City Southern (NYSE: KSU  ) are all over the eastern seaboard, and they're both getting skin in the game. CSX plans to spend $2.3 billion on wide-ranging expansion activities such as raising highway bridges, enlarging mountain tunnels, and clearing obstacles to make room for double-decker containers from the Midwest to the mid-Atlantic ports.

• [By Dan Caplinger]

  Kansas City Southern (NYSE: KSU  ) will release its quarterly report on Friday, with the stock having risen to levels it hasn't seen since it spun off its interest in Janus Capital back in 2000. But as much as healthy conditions in the railroad industry have helped Kansas City Southern earnings, there's another potential elephant in the room that's also contributing to investors' interest in the stock.

• [By Ben Levisohn]

  If January’s selloff was all about the emerging markets, February’s is all about the U.S, as fears of a weaker economy have helped drag down 3M (MMM), United Technologies (UTX), General Electric (GE), Whirlpool (WHR) and Kansas City Southern (KSU).

Top Mid Cap Stocks To Watch Right Now: Aeon Metals Ltd (AQR)

Aeon Metals Limited is an Australia-based company. Its principal activity is exploration of the Rawbelle tenement for porphyry copper/molybdenum mineralization near Monto, Queensland. The principal project is the Greater Whitewash Polymetallic Project, which consists of four deposits over a strike length of five kilometers and width of one kilometer. Its other projects include Kiwi Carpet, Kildare Project, Juicy Fruit, and Anomaly 7B. As of June 30, 2012, it controlled seven contiguous exploration permits for minerals (EPMs): 14628, 15920, 15921, 15922, 17001, 17702, 17060, which are 100% held by the Company and three contiguous EPMs at Kidare: 14627, 15919, and 18202. During the fiscal year ended June 30, 2012 (fiscal 2012), it drilled 37 holes for 9,112 meters, being7, 440 meters reverse circulation (RC) and 1672 meters of diamond drilling (DD) on Rawbelle tenement. As of June 30, 2012, Kiwi Carpet porphyry copper area has had 20 drill holes which returned grades of copper. Advisors' Opinion:

• [By Marc Chandler]

  3. The flash euro area PMIs, due Thursday, stand out as the most market sensitive economic data from the euro area. Although the sentiment has been running ahead of real sector data, slight positive growth has replaced the recent contraction. Next Wednesday, the ECB is expected to unveil the broad details of the Asset Quality Review (AQR). This is not a stress test. It is a preliminary review of the books of the banks for which it will soon have supervisory responsibilities. Definitions of risk-weighted assets various in the euro area and some uniformity is a necessary condition of a banking union. New stress tests will be conducted next year.

Top Mid Cap Stocks To Watch Right Now: P & F Industries Inc.(PFIN)

P&F Industries, Inc., through its subsidiaries, manufactures and sells tools and hardware products in the United States. The company operates in two segments, Tools and Other Products (Tools) and Hardware and Accessories (Hardware). The Tools segment manufactures, imports, and sells pneumatic hand tools, primarily for the industrial, retail, and automotive markets. Its product line includes sanders, grinders, drills, saws, impact wrenches, and pavement breakers; compressor air filters; and pipe and bolt dies, pipe taps, wrenches, vises and stands, pipe and tubing cutting equipment, hydrostatic test pumps, and replacement electrical components for pipe cutting and threading machines. This segment sells its products under the Florida Pneumatic, Universal Tool, ATP, Thaxton, THOR, and Eureka brand names to distributors, retailers, and private label customers through in-house sales personnel and manufacturers' representatives. The Hardware segment manufactures and imports door , window, and fencing hardware, including rollers, hinges, window operators, sash locks, custom zinc castings, and door closers. This segment also manufactures and imports interior wood and iron stair components, and related accessories, as well as kitchen and bath hardware; and manufactures stair products and distributes staircase components. Its products are sold through in-house sales personnel and manufacturers? representatives to distributors, retailers, and OEM customers. The company was founded in 1959 and is based in Melville, New York.

Advisors' Opinion:

• [By Monica Gerson]

  P&F Industries (NASDAQ: PFIN) is expected to report its quarterly results.

  INSYS Therapeutics (NASDAQ: INSY) is projected to report its Q1 earnings at $0.28 per share on revenue of $45.63 million.

Top Mid Cap Stocks To Watch Right Now: Titan International Inc (TWI)

Titan International, Inc. (Titan), incorporated on March 21, 1983, through its subsidiaries, is engaged in the manufacturing of wheels and tires. The Company operates in three segments: agricultural, earthmoving/construction and consumer. Titan produces a range of specialty products to meet the specifications of original equipment manufacturers (OEMs) and aftermarket customers in the agricultural, earthmoving/construction and consumer markets. Titan�� earthmoving/ construction market includes wheels and tires supplied to the mining industry, while the consumer market includes products for all-terrain vehicles (ATVs) and recreational/utility trailers. The Company�� customers include AGCO Corporation, CNH Global N.V., Deere & Company and Kubota Corporation.

In August 2012, it acquired Planet Corporation Group (Planet). Titan acquired 56% of the Corporation. In December 2012, Titan acquired 100% (Titan Europe).

Agricultural market

Titan�� agricultural rims, wheels and tires are manufactured for use on various agricultural and forestry equipment, including tractors, combines, skidders, plows, planters and irrigation equipment, and are sold directly to OEMs and to the aftermarket through independent distributors, equipment dealers and Titan�� own distribution centers. The wheels and rims range in diameter from 9 to 54 inches. Titan�� agricultural tires range from approximately 1 foot to approximately 7 foot in outside diameter and from 5 to 49 inches in width. The Company offers the added value of delivering a complete wheel and tire assembly to customers.

Earthmoving/construction market

The Company manufactures rims, wheels and tires for various types of off-the-road (OTR) earthmoving, mining, military and construction equipment, including skid steers, aerial lifts, cranes, graders and levelers, scrapers, self-propelled shovel loaders, articulated dump trucks, load transporters, haul trucks and backhoe loaders. The earthmoving/c! onstruction market is often referred to as OTR, an acronym for off-the-road. The Company provides OEM and aftermarket customers with a range of earthmoving/construction wheels ranging in diameter from 20 to 63 inches and in weight from 125 pounds to 7,000 pounds. The 63-inch diameter wheel is the manufactured in North America for the earthmoving/construction market. Titan�� earthmoving/construction tires range from approximately 3 feet to approximately 13 feet in outside diameter and in weight from 50 pounds to 12,500 pounds. The Company offers the added value of wheel and tire assembly for certain applications in the earthmoving/construction market.

Consumer market

Titan manufactures bias truck tires in Latin America, provides wheels and tires and assembles brakes, actuators and components for the domestic boat, recreational and utility trailer markets. Titan also offers select products for all-terrain vehicles (ATVs), turf, and golf car applications. Titan produces a variety of tires for the consumer market.

The Company competes with Carlisle Companies Incorporated, GKN Wheels, Ltd., Topy Industries, Ltd, Bridgestone/Firestone, Michelin, Pirelli, Berco and Caterpillar.

Advisors' Opinion:

• [By Travis Hoium]

  What: Shares of giant tire manufacturer Titan International (NYSE: TWI  ) fell 13% today after being downgraded by analysts.

  So what: Jefferies downgraded the stock from buy to hold, citing the probability of profit and sales pressure. William Blair also downgraded the stock to market perform and lowered its price target to $21. �

• [By Vera Yuan]

  Among a few stocks that had negative returns in the quarter, Veeco Instruments (VECO) and Titan International (TWI) are also among the smaller positions in the portfolio. VECO declined 11.1% in the June quarter, but not enough for us to add to the position.From FPA Capital Fund (Trades, Portfolio)�� Second Quarter 2014 Commentary.Also check out: FPA Capital Fund Undervalued Stocks FPA Capital Fund Top Growth Companies FPA Capital Fund High Yield stocks, and Stocks that FPA Capital Fund keeps buying Currently 0.00/512345

  Rating: 0.0/5 (0 votes)

• [By Vera Yuan]

  Among a few stocks that had negative returns in the quarter, Veeco Instruments (VECO) and Titan International (TWI) are also among the smaller positions in the portfolio. Titan, which declined 11.4% in the quarter and will be discussed later in this letter, is a relatively new stock in the portfolio and one that we added to as the share price declined.Among the stocks that we added to in the quarter were Atwood Oceanics (ATW) and Titan International (TWI).As mentioned above, Titan declined nearly 12% in the quarter and we added to the position as the stock weakened. As you may recall, we initiated the position in TWI in the fourth quarter of 2013 in the mid- teens. Despite our additional TWI purchases, we do not yet own a full position in the stock. However, we have plenty of capacity to take the stock to a normal full position, which is 3%, but this assumes the company earns the right to have more of your capital allocated to the position.The primary reason why TWI shares sold off recently is that the wheel and tire markets for large construction and mining equipment remain depressed. Investors had hoped that the off-road, large construction equipment and mining business would see some acceleration after the very cold winter season, but that does not appear to be the case. Tire inventory levels for large, off-road equipment were too high for dealers to be aggressive and purchase tires en masse earlier this year. However, there is some recent evidence that much of the excess tire inventory has been reduced to levels that now support some restocking.Our investment thesis for TWI is not predicated on the wheel and tire market for large, off-road equipment to come roaring back to levels experienced before the financial crisis. Rather we believe the assets TWI has accumulated over the past decade can be managed more efficiently and, therefore, profit margins can improve without a huge increase in revenues. We recently visited one of TWI�� Midwest tire facilities a

• [By Rich Duprey]

  Similarly, you certainly won't find Titan International's (NYSE: TWI  ) �Maurice "The Grizz" Taylor begging forgiveness for telling the French to go pound salt when asked to take over Goodyear's business there.�"How stupid do you think we are?" he asked. "The French workforce gets paid high wages but works only three hours. They get one hour for breaks and lunch, talk for three and work for three." He concluded, "You can keep the so-called workers."�

Don't Get Too Worked Up Over Powell Industries's Earnings

Although business headlines still tout earnings numbers, many investors have moved past net earnings as a measure of a company's economic output. That's because earnings are very often less trustworthy than cash flow, since earnings are more open to manipulation based on dubious judgment calls.

Earnings' unreliability is one of the reasons Foolish investors often flip straight past the income statement to check the cash flow statement. In general, by taking a close look at the cash moving in and out of the business, you can better understand whether the last batch of earnings brought money into the company, or merely disguised a cash gusher with a pretty headline.

Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Powell Industries (Nasdaq: POWL  ) , whose recent revenue and earnings are plotted below.

Source: S&P Capital IQ. Data is current as of last fully reported fiscal quarter. Dollar values in millions. FCF = free cash flow. FY = fiscal year. TTM = trailing 12 months.

Over the past 12 months, Powell Industries burned $15.6 million cash while it booked net income of $38.2 million. That means it burned through all its revenue and more. That doesn't sound so great. FCF is less than net income. Ideally, we'd like to see the opposite.

All cash is not equal
Unfortunately, the cash flow statement isn't immune from nonsense, either. That's why it pays to take a close look at the components of cash flow from operations, to make sure that the cash flows are of high quality. What does that mean? To me, it means they need to be real and replicable in the upcoming quarters, rather than being offset by continual cash outflows that don't appear on the income statement (such as major capital expenditures).

For instance, cash flow based on cash net income and adjustments for non-cash income-statement expenses (like depreciation) is generally favorable. An increase in cash flow based on stiffing your suppliers (by increasing accounts payable for the short term) or shortchanging Uncle Sam on taxes will come back to bite investors later. The same goes for decreasing accounts receivable; this is good to see, but it's ordinary in recessionary times, and you can only increase collections so much. Finally, adding stock-based compensation expense back to cash flows is questionable when a company hands out a lot of equity to employees and uses cash in later periods to buy back those shares.

So how does the cash flow at Powell Industries look? Take a peek at the chart below, which flags questionable cash flow sources with a red bar.

Source: S&P Capital IQ. Data is current as of last fully reported fiscal quarter. Dollar values in millions. TTM = trailing 12 months.

When I say "questionable cash flow sources," I mean items such as changes in taxes payable, tax benefits from stock options, and asset sales, among others. That's not to say that companies booking these as sources of cash flow are weak, or are engaging in any sort of wrongdoing, or that everything that comes up questionable in my graph is automatically bad news. But whenever a company is getting more than, say, 10% of its cash from operations from these dubious sources, investors ought to make sure to refer to the filings and dig in.

With questionable cash flows amounting to only 6.1% of operating cash flow, Powell Industries's cash flows look clean. Within the questionable cash flow figure plotted in the TTM period above, stock-based compensation and related tax benefits provided the biggest boost, at 12.8% of cash flow from operations. Overall, the biggest drag on FCF came from capital expenditures.

Best Sliver Companies To Invest In Right Now

A Foolish final thought
Most investors don't keep tabs on their companies' cash flow. I think that's a mistake. If you take the time to read past the headlines and crack a filing now and then, you're in a much better position to spot potential trouble early. Better yet, you'll improve your odds of finding the underappreciated home-run stocks that provide the market's best returns.

If you're interested in companies like Powell Industries, you might want to check out the jaw-dropping technology that's about to put 100 million Chinese factory workers out on the street – and the 3 companies that control it. We'll tell you all about them in "The Future is Made in America." Click here for instant access to this free report.

We can help you keep tabs on your companies with My Watchlist, our free, personalized stock tracking service.

Add Powell Industries to My Watchlist.

Best Food Companies To Buy For 2014

Who cares about falling jobless claims when Russia is massing troops along Ukraine’s border and banning food imports from the U.S.?

European Pressphoto Agency

Not the stock market. The S&P 500 fell 0.6% to 1,909.57, while the Dow Jones Industrial Average dropped 0.5% to 16,367.27 and is now down nine of the past 12 trading days. The Nasdaq Composite declined 0.5% to 4,334.97 and the small-company Russell 2000 dropped 0.5% to 1,119.76.

The losses came even as initial jobless claims fell to 289,000 last week, well below forecasts for a dip to 300,000. The four-week average dropped to 293,500, the lowest since 2006.

RBC’s Robert Stallard quotes the bank’s “geopolitical adviser” General Charles Vyvyan, who thinks the West needs to offer Vladimir Putin a way out:

Putin clearly will not, is not, able to respond to threats; he has invested too much in his nationalist rhetoric. If the West does not want a meltdown in global relations, it is up to them to offer him a lifeline. He knew, even if the vast majority of Russians did not know, that even before the impact of sanctions became apparent, his country was a failing state…I believe that Putin will pursue further offensive strategies in Ukraine which will attract yet more debilitating sanctions; and that he will then blame the disastrous situation in the country on the sanctions, thus absolving himself of all responsibility for a situation entirely of his own making.

Top 10 Life Sciences Companies To Buy For 2015: Amira Nature Foods Ltd (ANFI)

Amira Nature Foods Ltd., incorporated on February 20, 2012, is a provider of packaged Indian specialty rice, with sales in over 40 countries. It generates the majority of its revenue through the sale of Basmati rice, a long-grain rice grown only in certain regions of the Indian sub-continent. The Company sells its products, primarily in emerging markets, through a distribution network. It sells its Amira brand in more than 25 countries. The Company sells its Amira branded products to Indian retailers such as Bharti Wal-Mart, Big Bazaar, Metro Cash & Carry, Spar, Spencer's Retail, Star Bazaar (Tesco in India) and Total and retailers, such as Carrefour, Costco, Jetro Restaurant Depot, Lulu's and Smart & Final, and through the foodservice channel. It participates across the entire rice supply chain from the procurement of paddy to its storage, aging, processing into rice, packaging, distribution and marketing. In June 2013, the Company announced that it has launched Amira branded products in the United Kingdom. In January 2014, Amira Nature Foods Ltd acquired Basmati Rice GmbH.

The Company operates an automated and integrated processing and milling facility that is located in the vicinity of the key Basmati rice paddy producing regions of northern India. The facility spans a covered area of 310,221 square feet, with a processing capacity of 24 metric tons of paddy per hour. During the year ended March 31, 2012, 34% of its revenue was derived from sales in India, and 50.3% was derived from sales in the Europe, Middle East and Africa region, or EMEA, 14.3% was derived from sales in the Asia Pacific region, and 1.4% was derived from sales in North America.

Advisors' Opinion:

• [By Garrett Cook]

  Amira Nature Foods (NYSE: ANFI) shares shot up 12.76 percent to $14.67 after the company reported better-than-expected fourth-quarter earnings.

  Shares of Global Eagle Entertainment (NASDAQ: ENT) got a boost, shooting up 10.38 percent to $12.12 after the company and Boeing (NYSE: BA) announced a satellite connectivity partnership.

• [By Roberto Pedone]

  A consumer goods player that's starting to trend within range of triggering a big breakout trade is Amira Nature Foods (ANFI), a global provider of packaged Indian specialty rice, with sales in over 40 countries. This stock has been in play with the bulls over the last three months, with shares up 25%.

  If you take a look at the chart for Amira Nature Foods, you'll notice that this stock has been uptrending strong for the last five months, with shares soaring higher from its low of $7.44 to its recent high of $17.41 a share. During that uptrend, shares of ANFI have been making mostly higher lows and higher highs, which is bullish technical price action. Shares of ANFI have started to break out above some key near-term overhead resistance levels today at $15.92 to $16.25 a share. That move is quickly pushing shares of ANFI within range of triggering another big breakout trade.

  Traders should now look for long-biased trades in ANFI if it manages to break out above its all-time high of $17.41 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 226,387 shares. If that breakout triggers soon, then ANFI will set up to enter new all-time-high territory, which is bullish technical price action. Some possible upside targets off that breakout are $25 to $27 a share.

  Traders can look to buy ANFI off any weakness to anticipate that breakout and simply use a stop that sits right below its 50-day at $15.03 a share or around more key near-term support at $14.72 a share. One could also buy ANFI off strength once it starts to clear $17.41 a share with volume and then simply use a stop that sits a comfortable percentage from your entry point.

Best Food Companies To Buy For 2014: American Lorain Corp (ALN)

American Lorain Corporation (ALN), incorporated on February 4, 1986, is an integrated food manufacturing company. The Company develops, manufactures and sells food products, which includes chestnut products, convenience foods, including ready-to-cook (RTC) foods, ready-to-eat (RTE) foods and meals ready-to-eat (MRE)), and frozen food products. The Company conducts its production activities in China. Its products are sold in 26 provinces and administrative regions in China and 42 foreign countries. The Company derives its revenues from sales in China, Japan and South Korea. During the year ended December 31, 2011, the Company produced 254 products, including 16 new products in its chestnut and convenience foods segment. During 2011, it discontinued three products in the convenience segment. In February 2014, American Lorain Corp acquired a 51% interest in Athena Group.

The Company manufactures its products in six facilities in China, three of which are located in Junan County, Shandong Province, one in Luotian County, Hubei Province, one in Miyun County, Beijing City and one leased facility in Dongguan, Guandong Province. As of December 31, 2011, the Company manufactured its products using 26 production lines. Each production line is used to produce between 10 and 50 products. The Company operates three product lines: deep-freezing lines, canning lines and convenience food lines. The Company sells its products in all first-tier cities in China, including Beijing, Shanghai, Tianjin and Guangzhou. Its export sales destinations include Asia pacific, primarily Japan, South Korea and Malaysia, but also Singapore, Philippines, Indonesia and Australia; Europe, primarily Belgium and the United Kingdom, but also France, Germany, the Netherlands, Spain, Poland, and Denmark the Middle East, primarily Saudi Arabia, Kuwait and Israel; North America, including the United States and Canada.

ALN owns 100% of International Lorain Holding, Inc. (ILH). ILH wholly owns two Chinese operating subsi! diaries, Luotian Green Foodstuff Co., Ltd. (Luotian Lorain) and Junan Hongrun Foodstuff Co., Ltd. (Junan Hongrun), directly. Junan Hongrun, in turn, wholly owns Dongguan Green Foodstuff Co., Ltd. (Dongguan Lorain). In addition, together with Junan Hongrun, ILH wholly owns Beijing Green Foodstuff Co., Ltd. (Beijing Lorain), Shandong Greenpia Foodstuff Co., Ltd. (Shandong Greenpia), and owns approximately 80% of Shandong Green Foodstuff Co., Ltd. (Shandong Lorain) (Shandong Economic Development Investment Co. Ltd. owns approximately 20%).

Chestnut Products

During 2011, the Company produced 57 processed chestnut products. During 2011, this segment contributed 51.7% of its total revenues. The Company's products include its aerated open-bottom chestnuts, which are chestnuts packaged with nitrogen; sweetheart chestnuts, which are sweet preserved chestnuts; chestnuts in syrup, and golden chestnut kernels.

Convenience Foods

The Company's convenience food products include RTC food products, RTE food products and MRE food products. During 2011, the Company's RTCs included beef and lamb products, and its RTEs included bean products and pickle products. The Company's self heating MREs are primarily for military use since no cooking device or other ingredients are needed other than water. The Company also introduced microwavable MREs for civilian uses, such as camping, traveling and other situations. The Company produces various MREs based on Chinese cuisine, which include its pork with garlic sauce over rice and kungpao chicken with rice. The Company produced 138 convenience food products, during 2011, including 14 new products, such as filled buns and fried sweet potato.

Frozen Food Products

The Company produces a variety of frozen foods, including frozen vegetables, frozen fruits, frozen fish, and frozen meats. The Company produced 63 frozen food products in 2011. The Company's frozen foods included, during 2011, were frozen asparagus a! nd frozen! corn.

The Company competes with Hebei Liyuan, Foodwell Corporation, Weifang Langdong Food Co. Ltd., Yuyao Hongji Food Co. Ltd. and Yantai Pengshun Food Co. Ltd.

Advisors' Opinion:

• [By James E. Brumley]

  Truth be told, were it just today's 11% pop from American Lorain Corporation (NYSEMKT:ALN), it might not even be worth mentioning. It's not just today's 11% rally from ALN, though, that's made this stock so interesting. It's everything that's happened up until this point that may mean American Lorain deserves a spot at the top of your watchlist, if not in your portfolio.

Best Food Companies To Buy For 2014: Danone SA (DANOY)

Danone SA, incorporated on February 2, 1899, is a France-based company engaged in food processing activities. The Company operates in four business lines, including Fresh Dairy Products, Waters, Baby Nutrition and Medical Nutrition. The Fresh Dairy Products business line�� brands are Danone, Actimel, Activia, Danacol and Vitalinea. The Water business line offers brands, such as Evian, Volvic, Aqua, Bonafont, Font Vella and Lanjaron. The Baby Nutrition business line include Bledina, Gallia, Nutricia, Cow & Gate, Milupa, Mellin and Dumex brands. Medical nutrition business includes Nutricia, Nutrini, Nutrison, Fortimel, FortiCare, Fortisip, Neocate and Infatrini brands. As of December 31, 2009, the Company acquired Danone Clover and a 26.85% interest in Micropharma. In December 2010, the Company and Unimilk announced the finalization of the merger of their Fresh Dairy Product businesses.

In Europe the Company�� main markets are France, Spain, Germany, Italy, the Benelux countries, the United Kingdom, Poland and Russia. The Company�� product Actimel, the probiotic dairy product, if consumed daily, helps to strengthen the organism�� natural defenses. The Waters business line includes activities focused on natural or flavored mineral water and on fruit-flavored or tea drinks, with a positioning concerned with health benefits. The Company�� baby nutrition business line�� activities consist mainly of producing food for newborns and babies (infant milk formula, follow-on milk, and growing up milk). It also offers a diverse range of products for

children aged 6 to 36 months. Specially developed and clinically tested formulas have also been developed for babies suffering from milk protein intolerance. The Medical Nutrition business line develops nutritional products adapted to specific needs, namely those of hospitalized patients, in order to prevent malnutrition and to improve its consumers daily life.

The Company competes with Nestle, PepsiCo, Coca-cola, Abbott, Mead! Johnson and Fresenius.

Advisors' Opinion:

• [By Andrew Marder]

  Yogurt for breakfast is good. Coffee for breakfast is good. Yogurt-coffee might be crossing a hidden line, though. Thankfully, that's apparently not what�Starbucks (NASDAQ: SBUX  ) and Danone� (NASDAQOTH: DANOY  ) had in mind when they recently announced a plan to release yogurt together starting in 2014. The companies both get a benefit from the agreement, with Danone using Starbucks to get more exposure in the American market, while Starbucks gets another arrow in its food-quiver.

Best Food Companies To Buy For 2014: Post Holdings Inc (POST)

Post Holdings, Inc., incorporated on September 22, 2011, is a holding company. The Company is a manufacturer, marketer and distributor of branded ready-to-eat cereals in the United States and Canada. The Company�� portfolio of brands includes Honey Bunches of Oats, Pebbles, Great Grains, Grape-Nuts, Shredded Wheat, Raisin Bran, Golden Crisp, Alpha-Bits and Honeycomb. It markets and sells ready-to-eat cereal products in three different categories: sweetened, balanced and unsweetened. Its sweetened products include Pebbles, Honeycomb, Golden Crisp, Alpha-Bits and Waffle Crisp. Its balanced products include Honey Bunches of Oats, Post Selects, Great Grains and Shreddies. The Company�� unsweetened products include Post Shredded Wheat, Post Raisin Bran and Grape-Nuts. Effective January 1, 2014, the Company announced it has completed the acquisition of private label pasta manufacturer Dakota Growers Pasta Company, Inc. Effective January 2, 2014, Post Holdings Inc acquired Agricore United Holdings Inc from Viterra Inc, a unit of Glencore Xstrata PLC, and the transaction also included Dakota Growers Pasta Company, Inc. Effective January 1, 2014, Post Holdings Inc acquired Dymatize Enterprises LLC, a Farmers Branch-based manufacturer and wholesaler of nutrition supplement. Effective January 1, 2014, it acquired Dymatize Enterprises LLC and Golden Boy Foods Ltd.

Honey Bunches of Oats is in the ready-to-eat cereal market. The Company�� Pebbles brands include Cocoa and Fruity Pebbles. The products are manufactured through a flexible production platform consisting of four owned primary facilities and sold through a variety of channels, such as grocery stores, mass merchandisers, club stores, and drug stores.

Advisors' Opinion:

• [By Shamus Funk]

  Following the same line of logic, don't be surprised if Post (NYSE: POST  ) Grape-Nuts soon carry the GMO-free label. They are currently marketing Vintage Grape-Nuts which do not contain the likely GMO-laden isolated soy protein that is found in their current formulation of the cereal. Presumably with a little consumer demand, the transition back to the original recipe would be easy and enable the GMO-free label.

• [By Seth Jayson]

  Post Holdings (NYSE: POST  ) reported earnings on May 13. Here are the numbers you need to know.

  The 10-second takeaway
  For the quarter ended March 31 (Q2), Post Holdings missed estimates on revenues and missed estimates on earnings per share.

• [By Ali Berri]

  Equities Trading DOWN
  Shares of Post Holdings (NYSE: POST) were down 23.99 percent to $33.83 after the company reported a Q3 loss of $0.30 per share on revenue of $633.0 million. The company also announced its plans to acquire American Blanching Company. SunTrust Robinson Humphrey downgraded Post Holdings from Buy to Hold and lowered the price target from $70.00 to $45.00.

Best Food Companies To Buy For 2014: Wasgau Produktions & Handels AG (MSH)

Wasgau Produktions & Handels AG is a Germany-based retailer and producer of food articles. The Company divides its business activities into the two main segments Wholesale and Retail. The Wholesale�� businesses include seven Cash and Carry markets for restaurateurs and wholesale customers, as well as commercial businesses of the holding company WASGAU Produktions & Handels AG, which are supported by its subsidiary WASGAU Dienstleistungs & Logistik GmbH, active within warehouse management and transportation. The Operations within the Retail segment are mainly carried out through Company�� subsidiaries WASGAU Metzgerei GmbH and WASGAU Baeckerei & Konditorei GmbH, which produce and supply its stores with a variety of meats and bakery products, respectively. As of December 31, 2011, the Company operated through 24 affiliated companies and subsidiaries located in Germany. Advisors' Opinion:

• [By Rex Crum]

  The action helped push the Nasdaq (COMP) �up by 14 points to close at 3,943. The Philadelphia Semiconductor Index (COMP) �rose 0.4% and the Morgan Stanley High-Tech Index (MSH) �also closed with a small gain.

• [By Benjamin Pimentel]

  The Nasdaq Composite Index (COMP) �fell 0.4% to close at 4,052. The Morgan Stanley High Tech 35 Index (MSH) �and the Philadelphia Semiconductor Index (SOX) �each gained a fraction.

Best Food Companies To Buy For 2014: Biosev SA (BSEV3)

Biosev SA, formerly LDC Bioenergia SA, is a Brazil-based company active in the sugar and energy business. It is primarily engaged in the sugarcane processing. The Company produces sugar and ethanol, and supplies its products to domestic and international markets. Its refined sugar is sold under the Estrela brand name on the Brazilian retail market. The ethanol products comprise: hydrous ethanol, anhydrous ethanol and neutral ethanol. Other products from its plants include animal feed, dry yeast, molasses powder and bioelectricity from sugarcane bagasse. The Company�� customers include Nestle, Coca-Cola, AmBev, Kraft, Dori and Unilever, among others. The Company's production units are present in five Brazilian states: Mato Grosso do Sul, Sao Paulo, Minas Gerais, Paraiba and Rio Grande do Norte. Advisors' Opinion:

• [By Lucia Kassai]

  Biosev SA (BSEV3), Louis Dreyfus Holding BV�� Brazil unit, tumbled in its debut after giving investors in its initial public offering a money-back guarantee.

Top 10 Biotech Stocks To Watch Right Now

Wall Street started off the week on a sour note as investors remained cautious ahead of a slew of economic news slated for this week, most notably the Federal Reserve�� policy-setting committee statement on Wednesday as well as Friday�� monthly jobs report. In corporate news, biotech company Elan announced it that it will be acquired by U.S. based healthcare company Perrigo (PRGO). Also announcing an acquisition, Saks (SKS) agreed to be bought by Canada�� Hudson Bay. Meanwhile, Omnicom (OMC) and Publicis merged over the weekend to create the world�� largest advertising holding company. In economic news, pending home sales declined 0.4% in June .



Global Market Overview:�BJK Slumps After Wynn Resorts Earnings, XLE SlipsAhead of this week�� slew of economic reports, all three major U.S. equity indexes fell to close in positive territory.�The�Dow Jones Industrial Average ETF fell 0.15% as its underlying index traded in a narrow 75-point range.�The tech-heavy�Nasdaq�ETF slipped 0.24%, while the�S&P�500 ETF shed 0.31%.

Top 10 Shipping Stocks To Invest In Right Now: ANI Pharmaceuticals Inc (ANIP)

ANI Pharmaceuticals, Inc., incorporated on April 11, 2001, is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. In two facilities with combined manufacturing, packaging and laboratory capacity totaling 173, 00 square feet, the Company manufactures oral solid dose products, as well as liquids and topicals, including narcotics. Its other products include The Food and Drug Administration (FDA) approved testosterone gel, which is licensed to Teva Pharmaceuticals USA. In December 2013, the Company acquired 31 generic drug products from Teva Pharmaceuticals, which includes 20 solid-oral immediate release products, four extended release products and seven liquid products.

The Company performs contract manufacturing for other pharmaceutical companies. It has launched three products and has 11 products in development. The Company�� targeted areas of product development include narcotics, anti-cancers and hormones (potent compounds), and extended release niche generic product opportunities.

Advisors' Opinion:

• [By Monica Gerson]

  ANI Pharmaceuticals (NASDAQ: ANIP) reported that it has bought 31 generic drug products from Teva Pharmaceuticals (NYSE: TEVA) for $12.5 million in cash and a percentage of future gross profits. ANI Pharmaceuticals shares surged 5.14% to $18.00 in the after-hours trading session.

• [By Ben Levisohn]

  ANI Pharmaceuticals (ANIP) has climbed 8.9% to $18.80 after it said it would buy 31 generic drugs from Teva Pharmaceuticals (TEVA). Teva’s shares are little changed in pre-open trading.

Top 10 Biotech Stocks To Watch Right Now: Biota Pharmaceuticals Inc (BOTA)

Biota Pharmaceuticals, Inc., formerly Nabi Biopharmaceuticals, incorporated on March 14, 1969, is an anti-infective drug development company, with key expertise in respiratory diseases, particularly influenza. Biota developed the neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza. The Company�� researches include a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease and Hepatitis C (HCV) virus infections. In addition, Biota and Daiichi Sankyo co-own a range of second generation influenza anti-virals, of which the lead product lnavir, is approved for marketing in Japan.

The Company�� products include Zanamivir, Inavi, Phoslyra, BioStar OIA FLU and BioStar OIA FLU A/B. Zanamivir is a neuraminidase inhibitor for the treatment and prophylaxis of influenza marketed as Relenza by GlaxoSmithKline. Inavi (laninamivir) is a neuraminidase inhibitor marketed by Daiichi Sankyo in Japan. Phoslyra is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (ESRD). BioStar OIA FLU and BioStar OIA FLU A/B are influenza diagnostic tests, which are marketed by Inverness Medical as part of their BioStar product range.

Relenza is delivered directly to the primary site of infection on the lungs, using a Disk Inhaler device. Relenza is approved in over 50 countries for the treatment of influenza, including in the United States, the European Union, Japan and Australia. Relenza is also approved for use as a preventative (prophylactic) treatment against influenza. Inavir is approved for sale in Japan for the treatment of influenza in adults and children. Daiichi Sankyo has applied to sell Inavir in Japan for the prevention of influenza.

PhosLo and Phoslyra are different dose forms of calcium acetate; a phosphate binder approved in multiple countries for the control of hyperphosphatemia (high serum phosphate) in patients with end stage renal disease (ESRD). PhosLo and Pho! slyra were sold to Fresnius Medical Care. Biota, together with its Japanese based partner, Daiichi Sankyo, have developed an inhaled antiviral compounds for influenza, called long acting inhaled neuraminidase inhibitors (LANI). Biota's human rhinovirus (HRV) drug for the prevention and treatment of the causes of the common cold, BTA798, has completed Phase I, Phase IIa and Phase IIb clinical trials.

Advisors' Opinion:

• [By gurujx]

  Biota Pharmaceuticals Inc (BOTA) Reached the 3-year Low of $2.42

  The prices of Biota Pharmaceuticals Inc (BOTA) shares have declined to close to the 3-year low of $2.42, which is 93.3% off the 3-year high of $34.92.

Top 10 Biotech Stocks To Watch Right Now: Insys Therapeutics Inc (INSY)

Insys Therapeutics, Inc., incorporated on June 15, 1990, is a pharmaceutical company that develops and seeks to commercialize pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The Company�� pharmaceuticals portfolio consists of one approved product and a number of product candidates targeting cancer-supportive care and cancer therapy. The Company�� product candidate includes Subsys, Dronabinol SG Capsule, Dronabinol RT Capsule, Dronabinol Oral Solution, Dronabinol Inhalation Device, and Dronabinol IV Solution. The Company is also developing cancer therapeutics, which is LEP-ETU, a formulation of paclitaxel, the active ingredient in the cancer drugs Taxol and Abraxane. On August 19, 2011, the Food & Drug Administration (FDA) approved its Dronabinol SG Capsule product, a generic equivalent to Marinol, for the treatment of chemotherapy induced nausea and vomiting (CINV), and anorexia associated with weight loss in patients with acquired immune deficiency syndrome (AIDS).

Subsys

The Company's Subsys is a single-use product that delivers fentanyl, an opioid analgesic, in seconds for transmucosal absorption underneath the tongue. Subsys is a transmucosal product to show pain relief when measuring the sum of pain intensity difference at five minutes in a Phase 3 breakthrough cancer pain (BTCP) clinical trial using fentanyl.

Dronabinol Product Family

The Company has an approved dronabinol product and is developing several dronabinol product candidates for the treatment of CINV and appetite stimulation in patients with AIDS, as well as other indications where dronabinol could have potential therapeutic benefits. Dronabinol, the active ingredient in Marinol, is a synthetic cannabinoid whose chemical name is delta-9-tetrahydrocannabinol (THC). Its portfolio consists of its Dronabinol SG Capsule product and Dronabinol RT Capsule product candidate, which are intended to be generic equi! valents to Marinol, in addition to three formulations, including Dronabinol Oral Solution. Dronabinol SG Capsule is a dronabinol soft gelatin capsule intended to be a generic equivalent to Marinol. Dronabinol RT Capsule is a dronabinol soft gel capsule that is stable at room temperature. Dronabinol Oral Solution is a ynthetic THC in an oral liquid formulation.

Cancer Therapeutics

In addition to its cancer-supportive care products, the Company intends to develop cancer therapeutics targeting limitations of existing commercial products. LEP-ETU, it advanced cancer therapeutic, is a NeoLipid liposomal, or microscopic membrane-like structure created from lipids, formulation that incorporates paclitaxel. LEP-ETU completed a Phase 2 clinical trial of 70 patients with metastatic breast cancer.

The Company competes with Cephalon, Inc., BioDelivery Sciences International, Inc., ProStrakan Group plc, Nycomed International Management GmbH, Archimedes Pharma Ltd., TEVA Pharmaceuticals USA, Watson Pharmaceuticals, Inc., AcelRx Pharmaceuticals, Inc., Akela Pharma Inc., Abbott Laboratories, Pharmaceutical International, Inc., Par Pharmaceutical Companies Inc., sanofi-aventis, Eisai Inc., Helsinn Group, Roche Holding AG, Par Pharmaceutical Companies Inc., GlaxoSmithKline plc, ProStrakan Group plc, Merck & Co, GW Pharmaceutical, A.P. Pharma, Inc., Aphios Corp., Roche Holding, Tesaro, Inc., Cornerstone Pharmaceutical, Inc., Bristol-Myers Squibb, Celgene Corporation, Laboratories, Amgen Inc., AstraZeneca PLC., Bayer AG, Biogen Idec Inc., Eisai Co., Ltd., F. Hoffmann- LaRoche Ltd., Johnson and Johnson, Merck and Co., Inc., Novartis AG, Onyx Pharmaceuticals Inc., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd.

Advisors' Opinion:

• [By Matt Jarzemsky]

  Among companies that went public in the U.S. last year, FireEye has seen the second-biggest share rally since its IPO, trailing only pharmaceutical company Insys Therapeutics Inc.(INSY)

Top 10 Biotech Stocks To Watch Right Now: AMAG Pharmaceuticals Inc.(AMAG)

AMAG Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia (IDA). Its principal product includes Feraheme (ferumoxytol) injection for intravenous (IV) use, which was approved for marketing in the United States in June 2009 by the U.S. Food and Drug Administration, for use as an IV iron replacement therapy for the treatment of IDA in adult patients with chronic kidney disease (CKD). The company is pursuing marketing applications in the European Union, Canada, and Switzerland for Feraheme for the treatment of IDA in CKD patients. AMAG Pharmaceuticals was founded in 1981 and is based in Lexington, Massachusetts.

Advisors' Opinion:

• [By Monica Gerson]

  AMAG Pharmaceuticals (NASDAQ: AMAG) shares fell 16% to $18.38 in the pre-market trading after the company received a CRL from the FDA for the supplemental NDA for Feraheme for broader IDA indication.

• [By John Udovich]

  The start of 2014 shows that biotech is still a hot area with the sector along with small cap biotech stocks like AMAG Pharmaceuticals, Inc (NASDAQ: AMAG), Mast Therapeutics Inc (NYSEMKT: MSTX), Cell Therapeutics Inc (NASDAQ: CTIC), Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) and TNI BioTech (OTCMKTS: TNIB) producing news or returns�plus Auspex Pharmaceuticals (NASDAQ: ASPX), Cara Therapeutics (NASDAQ: CARA), Egalet (NASDAQ: EGLT), Flexion Therapeutics (NASDAQ: FLXN) and Ultragenyx Pharmaceutical (NASDAQ: RARE) are among the (many�� planned biotech IPOs that have recently been announced publicly:

Top 10 Biotech Stocks To Watch Right Now: Pain Therapeutics Inc (PTIE)

Pain Therapeutics, Inc., incorporated in May 1998, is a biopharmaceutical company that develops drugs. The Company has four drug candidates in clinical programs, including REMOXY, abuse-resistant hydromorphone, abuse-resistant hydrocodone and a radio-labeled monoclonal antibody to treat metastatic melanoma. It is also working on a new treatment for patients with hemophilia. The Company�� lead drug candidate is REMOXY, which is a painkiller. It has collaboration agreement with King Pharmaceuticals, Inc. (King) develops and commercializes REMOXY and other opioid painkillers. The Company and King jointly managed a Phase III clinical program and New Drug Application (NDA) submission for REMOXY. It is also developing a pipeline of drug candidates in the area of oncology and hematology. It owns all commercial rights to its pipeline of drug candidates in oncology and hematology. As of December 31, 2010, the Company leased approximately 30,700 square feet of space in San Mateo, California and all of its operations are located in San Mateo.

REMOXY

REMOXY is a controlled-release oral capsule form of oxycodone in a highly viscous liquid formulation matrix that includes excipients. It is formulated to help address issues of abuse and misuse of time-release oxycodone tablets. REMOXY�� capsule dosage form provides therapeutic drug levels of oxycodone on a twice-daily dosing schedule, while resisting the rapid increases in plasma levels of oxycodone associated with common methods of abuse and misuse. Its formulation also resists delivery by unapproved routes of administration, such as injection, snorting or inhalation.

Metastatic Melanoma

The Company is developing a drug candidate called PTI-188 to treat metastatic melanoma, a form of skin cancer. PTI-188 is a monoclonal antibody linked to a radioisotope, intended to deliver doses of radiation lethal to melanoma tumors without harming normal tissue. In March 2010, the Company announced data from two open-label! , dose-escalating Phase I studies conducted in Israel to assess the safety, pharmacokinetics, dosimetry and anti-tumor activity of PTI-188. During the year ended December 31, 2010, the second study was completed. The technology used in this program was developed at the Albert Einstein College of Medicine (AECOM). It had licensed worldwide commercial rights to this technology from AECOM.

Hemophilia

The Company has a gene transfer program, initially developed at Stanford University, focused at correcting a genetic disorder in which patients are unable to stop bleeding. During 2010, it conducted a variety of pre-clinical studies with this technology. The Company has licensed worldwide commercial rights to the technology used in this program from Poetic Genetics, LLC (Poetic).

Other product candidates

The Company�� alliance with King includes development of three other abuse-resistant opioid product candidates: hydromorphone, hydrocodone and oxymorphone. Its abuse-resistant formulations of hydromorphone and hydrocodone have completed Phase I clinical trials. In January 2011, the Company announced that the Food and Drug Administration (FDA) had accepted its investigational IND, for abuse-resistant oxymorphone.

The Company competes with Roxane Laboratories, Purdue Pharma, King Pharmaceuticals, Inc., Abbott Laboratories, Cephalon, Endo Pharmaceuticals, Teva Pharmaceuticals, Elkins-Sinn, Watson Laboratories, Ortho-McNeil Pharmaceutical and Forest Pharmaceuticals.

Advisors' Opinion:

• [By Jessica Alling]

  Elsewhere, Pfizer is evaluating its continued partnership on an experimental oxycodone capsule, Remoxy. The drug is an extended-release formula that is targeted at reducing abuse of the painkiller. After years of setbacks and postponements for FDA approval, Pfizer is weighing its options. Its partners for the drug, Pain Therapeutics (NASDAQ: PTIE  ) and Durect, have both fallen heavily due to the news, with Pain Therapeutics falling more than 50% -- its largest decline ever.

• [By Sean Williams]

  However, all isn't well when it comes to the future of abuse-resistant painkiller Remoxy, which was developed by Pain Therapeutics (NASDAQ: PTIE  ) , using Durect's�special technology-based gel capsule to prevent abuse, and is licensed by Pfizer (NYSE: PFE  ) . Remoxy has been rejected twice by the FDA -- the most recent coming in mid-2011 -- and Pfizer commented this morning that if it were to seek reapproval for the drug it wouldn't be for at least two more years. Given Pfizer's extensive product pipeline, losing Remoxy wouldn't be a big deal. For micro-cap clinical-stage companies like Pain Therapeutics and Durect, it'd be a gigantic blow. Fittingly, Pain Therapeutics and Durect shares imploded by 50% and 34%, respectively, on Friday.

Top 10 Biotech Stocks To Watch Right Now: Stemline Therapeutics Inc (STML)

Stemline Therapeutics, Inc. (Stemline), incorporated on August 8, 2003, is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics that target both cancer stem cells (CSCs) and tumor bulk. The Company is developing two clinical-stage product candidates, SL-401 and SL-701, for which it holds global marketing rights. The indication for SL-401, a biologic-drug conjugate, is acute myeloid leukemia (AML). The indications for SL-701, a synthetic peptide vaccine, are pediatric and adult brain cancer. It has a platform, StemScreen, for the discovery of CSC-targeted compounds, from which it has discovered or validated several of its clinical and preclinical product candidates. Stemline�� StemScreen consists of StemScreen-1 and StemScreen-2 for the identification of CSC-directed compounds.

SL-301 is a small molecule gamma-secretase inhibitor that inhibits Notch, a pathway expressed by CSCs and tumor bulk of multiple cancer types. SL-101 is a monoclonal antibody-based (mAb -based) compound that targets CD123 and has shown in vitro activity against certain hematologic cancers. SL-201 is a small molecule active against certain hematologic and solid tumor types. SL-601 is a mAb-based compound that targets a cell surface marker on bladder CSCs, which is also expressed on a variety of other solid tumor types. It has also in-licensed certain intellectual property directed to mAb-based therapeutics to validated oncology targets, including Glypican-3, Tie-1, CD133, Frizzled, Smoothened and Patched.

SL-401 - An IL-3R-Directed Compound Targeting Cancer Stem Cells and Tumor Bulk

SL-401 is a clinically active biologic-drug conjugate consisting of human interleukin-3 (IL-3) genetically linked to a truncated version of diphtheria toxin. SL-401 targets the IL-3 receptor (IL-3R), which is overexpressed on both the CSCs and tumor bulk of multiple hematologic cancers, including AML. SL-401 has demonstrated preclinical in vit! ro and in vivo activity against both leukemia blasts (which includes tumor bulk) and CSCs of a range of human leukemia cell lines and primary leukemia cells from patients.

SL-701

SL-701 is a clinically active synthetic peptide vaccine that targets several epitopes on CSCs and tumor bulk of brain cancer. In two completed Phase 1/2 clinical trials, SL-701 demonstrated single agent anti-tumor activity in pediatric patients with newly diagnosed brainstem glioma (BSG) and other high-grade gliomas (HGGs) and in adult patients with refractory or recurrent GBM, and other HGGs.

StemScreen-1

StemScreen-1 is a drug discovery platform designed to identify CSC-targeted compounds based on the isolation of CSCs and evaluation of CSC gene expression profiles. CSCs are isolated from primary tumor tissue or cell lines, and then subjected to gene expression analysis using a variety of technologies, including microarray. A control tissue, such as normal bone marrow is analyzed as a comparator against the gene expression profile of the isolated CSCs. These data are then interfaced with an information base of compounds and their mechanisms of action (that is which gene products and pathways they impact). It has utilized StemScreen-1 to discover a number of its preclinical drug candidates. These include SL-201, SL-301, and SL-601. In addition, SL-401 demonstrated activity against CSCs as determined by both an in vitro colony formation and in vivo animal implantation assay, thereby validating certain StemScreen-1 anti-CSC assays.

StemScreen-2

StemScreen-2 is a high throughput drug discovery platform it is developing to discover anti-CSC compounds. StemScreen-2 utilizes a cell-based assay that can track and follow CSCs in their natural state during high throughput screening. In particular, StemScreen-2 utilizes a CSC-specific promoter linked to a reporter as a method for identifying and following CSCs in their native environment of surrounding tumor b! ulk. In t! his way, StemScreen-2 enables the identification of compound hits, in a high throughput manner, with anti-CSC activity.

The Company competes with Boston Biomedical, Inc., Eclipse Therapeutics, Inc., OncoMed Pharmaceuticals, Inc., Verastem, Inc., Astellas Pharma US, Inc., Boehringer Ingelheim GmbH, Dainippon Sumitomo Pharma Co. Ltd., Geron Corp., GlaxoSmithKline plc, ImmunoCellular Therapeutics, Ltd, Macrogenics Inc., Amgen, Inc., Pfizer Inc., Roche Holding AG, Sanofi U.S. LLC., Cyclacel Pharmaceuticals, Inc., Sunesis Pharmaceuticals Inc., Clavis Pharma ASA, Ambit Biosciences Corporation, Celgene Corporation, Eisai Co. Ltd., Celator Pharmaceuticals, Inc., Merck & Co., Inc., Eisai Co., Inc., Roche Holding AG, Novartis AG and Celldex Therapeutics, Inc.

Advisors' Opinion:

• [By Jay Silverman]

  Some of the biggest leaders in that field, and there have been dozens in fields, if not more this year, such as Bluebird (BLUE) and Stemline Therapeutics (STML) and have all pulled back to significantly lower levels; even below, in Bluebird's case, the price that had actually opened up as an IPO, even though it's above its IPO price.

• [By David Zeiler]

  3. Stemline Therapeutics Inc. (Nasdaq: STML): This biotech develops drugs that target cancer stem cells and tumors. Stemline went public January 29 at $10 a share and rose just 11.78% on its first day. But STML has climbed steadily since, and currently trades at $37.46, up 274.6% from its IPO price.

• [By Keith Speights]

  Best-performing biotech IPO
  Stemline Therapeutics� (NASDAQ: STML  ) has only traded publicly this year, but what a year it's been. The stock's performance ranks Stemline as the best-performing biotech IPO so far in 2013. This week has been pretty good also, with shares moving up by 28%.

Top 10 Biotech Stocks To Watch Right Now: Hemispherx Biopharma Inc (HEB)

Hemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company engaged in the clinical development of new drugs therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Hemispherx focuses on two core pharmaceutical technology platforms Ampligen and Alferon N Injection.The commercial focus for Ampligen includes application as a treatment for Chronic Fatigue Syndrome (CFS) and as an influenza vaccine enhancer (adjuvant) for both therapeutic and preventative vaccine development. Alferon N Injection is a United States Food and Drug Administration (FDA) approved product with an indication for refractory or recurring genital warts. Alferon LDO (Low Dose Oral) is a formulation under development targeting influenza. It has three subsidiaries BioPro Corp., BioAegean Corp., and Core BioTech Corp. The Company's foreign subsidiary is Hemispherx Biopharma Europe N.V./S.A.

Ampligen

Ampligen is an experimental drug, which is undergoing clinical development for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Over 1,000 patients have participated in the Ampligen clinical trials representing the administration of more than 90,000 doses of this drug. The Company is also engaged in ongoing, experimental studies assessing the efficacy of Ampligen against influenza viruses.

Alferon N Injection

Alferon N Injection is the registered trademark for the Company's injectable formulation of natural alpha interferon. Interferons are a group of proteins produced and secreted by cells to combat diseases. The Company's natural alpha interferon is produced from human white blood cells. Alferon N Injection [Interferon alfa-n3 (human leukocyte derived)] is a highly purified, natural-source, glycosylated, multi-species alpha interferon product.

Alferon LDO (Low Dose Oral)

Alferon LDO [Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)]! is an experimental low-dose, oral liquid formulation of Natural Alpha Interferon and like Alferon N Injection should not cause antibody formation, which is a problem with recombinant interferon. It is an experimental immunotherapeutic that works by stimulating an immune cascade response in the cells of the mouth and throat, enabling it to bolster systemic immune response through the entire body by absorption through the oral mucosa.

The Company competes with Pfizer, GlaxoSmithKline, Merck, AstraZeneca, Baxter International, Fletcher/CSI, AVANT Immunotherapeutics, AVI BioPharma and Genta.

Advisors' Opinion:

• [By MONEYMORNING]

  Hemispherix Biopharma Inc. (NYSE: HEB) is a specialty pharmaceutical company. It engages in the clinical development of new drug therapies based on natural immune system enhancing technologies and targets the treatment of viral and immune-based clinical disorders. The Philadelphia, Pa.-headquartered company gained widespread attention over the last several months for its work on flu research. Its flagship products include Alferon N Injection, approved by the FDA for a category of sexually transmitted disease infection. Experimental treatments include Ampligen and Oragens, in development stages for the potential treatment of global viral diseases and disorders of the immune system including human papilloma virus, human immunodeficiency virus, chronic fatigue syndrome, hepatitis, and influenza. Shares have traded as low as $0.18 and as high as $0.55 over the last year. At last check, shares were changing hands around $0.50 on volume of 2 million shares.

• [By Matt Egan]

  Shares of Hemispherx Biopharma (HEB) soared 11% on Wednesday amid the rising Ebola fears. Earlier this week, the company announced a series of research collaborations aimed at developing treatments to fight Ebola.